← back to search

Anna Turkina

Federal State Institution Hematology Research Center ·
Area of research
Hematology · Genetics
Research interest
Research interests include Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Eosinophilic Disorders and Syndromes, and Acute Lymphoblastic Leukemia research.
h-index
26
citations
5,100
works
365
NIH funding
primary concept
Medicine
email

Recent publications

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Leukemia 2025cited by 68position: middledoi
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
JAMA Oncology 2024cited by 25position: middledoi
Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)
Blood 2023cited by 13position: middledoi
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
Blood 2021cited by 192position: middledoi
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Leukemia 2020cited by 1,490position: middledoi
Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
Journal of Clinical Oncology 2020cited by 20position: middledoi
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Leukemia 2015cited by 255position: middledoi
Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
American Journal of Hematology 2015cited by 82position: middledoi
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up
American Journal of Hematology 2014cited by 116position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jörge E. Cortes · Cecil College6 papers (2014–2024)Elza Lomaia · Federal Almazov North-West Medical Research Centre4 papers (2020–2024)Hagop M. Kantarjian · The University of Texas MD Anderson Cancer Center3 papers (2014–2023)Dong‐Wook Kim · University Health Network3 papers (2014–2020)Eric Leip · Pfizer (United States)2 papers (2014–2015)Gianantonio Rosti · Policlinico S.Orsola-Malpighi2 papers (2020–2021)Vivian G. Oehler · Yale Cancer Center2 papers (2023–2024) · 2 papers (2023–2024)Jeffrey H. Lipton · Princess Margaret Cancer Centre2 papers (2020–2021) · 2 papers (2014–2015)Michael J. Mauro · Center for Discovery2 papers (2020–2021) · 2 papers (2023–2024)Anthony M. Hunter · Emory University2 papers (2023–2024)Yifan Zhai · Sun Yat-sen University Cancer Center2 papers (2023–2024)Christopher Arthur · Royal North Shore Hospital2 papers (2020–2021)Omer Jamy · Birmingham VA Medical Center2 papers (2023–2024)Andreas Hochhaus · Institute of Hematology & Blood Diseases Hospital2 papers (2020–2021)Carlo Gambacorti‐Passerini · Azienda Ospedaliera San Gerardo2 papers (2014–2015) · 2 papers (2023–2024)Tim H. Brümmendorf · Diakonie-Klinikum Stuttgart2 papers (2014–2015)